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Naujų psichoaktyvių medžiagų kontrolės  
mechanizmai ir metodai
Santrauka. Straipsnis skirtas apžvelgti tarptautinius ir nacionalinius mechanizmus, 
naudojamus įtraukti naujas psichoaktyvias medžiagas į kontroliuojamų medžiagų ratą. 
Autoriai apžvelgia Jungtinėse Tautose, Europos Sąjungoje, Europos ir kitose valstybėse 
funkcionuojančias naujų psichoaktyvių medžiagų kriminalizavimo sistemas, taip pat 
siūlo tam tikrus teisinius būdus kaip kriminalizaciją Europos Sąjungoje padaryti pa-
prastesne. Straipsnyje taip pat apžvelgiamos ir analizuojamos teisinės formuluotės, Eu-
ropos ir kitose valstybėse vartojamos naujoms psichoaktyvioms medžiagoms apibrėžti: 
katalogo metodas, kriminalizacija pagal bendrus požymius, visaapimantys draudimai, 
reguliavimas pasitelkiant vartotojų teisių apsaugos ir sveikatos apsaugos teisės normas, 
teisinių rinkų naujoms psichoaktyvioms medžiagoms kūrimas.
Pagrindiniai žodžiai: naujos psichoaktyvios medžiagos, kriminalizacija, narkotikų 
politika.
Introduction
The legal definition of new psychoactive substances as a tool for crimi-
nalization and control of this rapidly changing phenomenon has been under 
consideration both in many European states and on the international scale 
since 1920s already (Madras, 2017). However, developments taking place in 
chemistry, biology, pharmacology and related fields during the latest decades 
have placed the issues under consideration on the forefront of the control and 
prevention of drug abuse. By the end of 2016, the European Monitoring Cen-
tre for Drugs and Drug Addiction monitored more than 620 new psychoactive 
substances on the European drug market (EMCDDA, 2017), up to December 
2017, more than 800 substances have been reported to the United Nations 
Office on Drugs and Crime Early Warning Advisory (EWA) on New Psycho-
active Substances by Governments, laboratories and partner organisations. 
However, up to March 2017, the United Nations Commission on Narcotic 
Drugs decided to place only 27 new psychoactive substances under interna-
tional control (United Nations Office on Drugs and Crime, 2018). 
Changes in the markets of new psychoactive substances are extremely rap-
id. NPS detected only a year ago are no longer present on the market, and the 
majority are currently limited to few countries and available for a short period 
of time.
All the aforementioned determines the needs to search for the most ef-
fective procedures and methods to criminalize newly emerging psychoactive 
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substances in a timely manner to be of importance. Although the theme has 
attracted some attention in literature, comprehensive analysis of legal attitudes 
adapted in different states is lacking and this article is aimed to fill the gap.
1. The Term and Notion of New  
Psychoactive Substances
The term and notion of new psychoactive substances has not been uni-
versally accepted in the literature. NPS include herbal substances (e.g. 
mushroom-based substances) or substances of synthetic origin (e.g. mephe-
drone) (Winstock et al., 2010). The term „new“ does not always mean that 
substances have been produced recently and for the first time (Chatwin et al., 
2017). Accordingly, NPS are considered to be substances that have existed for 
decades, but have recently become available to a wider circle of users or have 
recently become popular. The dangers of NPS stem from the fact that they 
represent a legal substitute for traditional drugs, because their effect is similar 
to that of controlled psychoactive substances (Deluca et al., 2012). It is about 
the legal substitution of traditional drugs, because at the moment of selling 
or consuming NPS, they are not on the list of controlled substances, which is 
why the people who import, manufacture, distribute or consume new drugs 
cannot be prosecuted. They are sold in specialized shops, the so-called „head 
shops“ (Alexandrescu, 2017). One of the main reasons for the huge popularity 
and increasing number of NPS on the drug market is exactly the legal status of 
NPS, because distributors and users of new drugs do not risk being prosecuted 
and punished (Soussan et al., 2018).
However, it has been pointed out in the scientific literature that the term 
„legal highs“ is inappropriate for several reasons: 1) the status of NPS in relati-
on to the regulations governing this area means only current legality, in other 
words, it is only a matter of time when new drugs will be added to the list of 
banned substances; 2) the adjective „legal“ can mislead drug users regarding 
the ban on substance use, if they have been added to the list of controlled 
substances; 3) dealers misuse this name because they use it for marketing pur-
poses, emphasizing no prosecution risk for users; 4) this term is misleading re-
garding the harmful effects of NPS because it gives the illusion that new drugs 
are not dangerous because they are „legal“ (Corazza et al., 2013).
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2. New Psychoactive Substances:  
International Mechanisms of Criminalization
Most of the known opioids are enlisted as narcotic or psychotropic sub-
stances in the Schedules of the 1961 Single Convention on Narcotic Drugs (as 
amended by the 1972 Protocol), and 1971 Vienna Convention on Psychotropic 
Substances as subject to measures of control of different scope (International 
Narcotics Control Board, 2016). These documents are often referred to in legal 
acts both on the EU and national level of Member States (European Council 
2001; European Council, 2005; Código penal de España, 1967; Forskrift om 
narkotika, 2013). Taking into account that both conventions establish that the 
Schedules are to be modified by the Commission on Narcotic Drugs of the 
Economic and Social Council of the United Nations without a special ratifica-
tion of the changes by the UN Member States (Single Convention on Narcotic 
Drugs, 1961; Convention on Psychotropic Substances, 1971), it could be con-
sidered as one of the first examples of a universal legislative process. It should 
however be noted that some Member States of the EU (e.g. Malta, the Neth-
erlands) do provide for a separate national procedure for the changes of the 
UN and EU schedules to have effect in the respective Member States (Danger-
ous Drugs Ordinance, 1939; Opiumwet, 1928). Many EU Member States (e.g. 
Lithuania or Slovenia) provide for the same procedure indirectly, i.e. without 
giving a direct link to the UN conventions and EU council decisions (Lietuvos 
Respublikos narkotinių ir psichotropinių medžiagų kontrolės įstatymas, 2019; 
Zakon o proizvodnji in prometu s prepovedanimi drogami, 1999).
These national approaches adopted could raise some doubts whether they 
are not in contravention to the aforementioned conventions itself. For exam-
ple, the 1961 Single Convention on Narcotic Drugs (as amended by the 1972 
Protocol), establishes that decisions of Commission on Narcotic Drugs of the 
Economic and Social Council of the United Nations “become effective with 
respect to each Party on the date of its receipt of such communication” (Art. 3, 
para. 7). The 1971 Vienna Convention on Psychotropic Substances is slightly 
less rigid in this regard. Art. 2 para. 7 of the Convention establishes that every 
decision of the Commission on Narcotic Drugs to enlist a new substance in 
one of the schedules “shall become fully effective with respect to each Party 
180 days after the date of such communication”, however acknowledges a right 
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of every State Party to avoid new obligations arising from a certain decision if 
a State Party “has transmitted to the Secretary-General a written notice that, 
in view of exceptional circumstances, it is not in a position to give effect with 
respect to that substance to all of the provisions of the Convention applicable 
to substances in that Schedule.” 
The aforementioned provisions of the 1961 Single Convention on Narcotic 
Drugs (as amended by the 1972 Protocol), and 1971 Vienna Convention on 
Psychotropic Substances could be considered to create a system where new 
psychoactive substances in every state signatory to the conventions are crimi-
nalized by a decision of an international body – the Commission on Narcotic 
Drugs of the Economic and Social Council of the United Nations (at least in 
states that directly link their laws on narcotic drugs to the schedules estab-
lished by the convention). 
A similar procedure has been created inside the European Union. The 
Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, 
risk-assessment and control of new psychoactive substances establishes that 
decisions to submit new psychoactive substance to control measures are to be 
made by the Council qualified majority acting on an initiative presented by the 
Commission. Some Member States also follow the attitude formulated towards 
recognition of new narcotic and psychotropic substances in the UN conven-
tions. For example, the Narcotics Act of Finland establishes that “the term 
‘psychoactive substance’ prohibited on the consumer market includes sub-
stances used for drug use which may be hazardous to health and which have 
been notified for surveillance pursuant to the Council Decision” (Huumau-
sainelaki, 2008). However, most of the Member States still consider the afore-
mentioned decisions by the European Council as a basis for a separate national 
regulation to be passed, e.g. the Lithuanian Law on Control of Narcotic and 
Psychotropic Substances does not provide no alternative procedure for a new 
psychotropic substance to be placed under measures of control apart through 
a formal decision of the Ministry of Health (Narkotinių ir psichotropinių 
medžiagų kontrolės įstatymas, 2019). Member States that establish a special 
“emergency” procedure also follow the rule that a national legal decision to en-
list certain new psychotropic substance as a substance under legal control shall 
be adopted, e.g. the Latvian law on the order of legal circulation of narcotic 
and psychotropic substances and drugs establishes that the lists of narcotic 
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and psychotropic drugs are to be established by the Government; however, the 
Center for Prevention and Control Diseases is empowered to decide that the 
manufacture, acquisition, storage, transportation, transfer or distribution of 
new psychoactive substances that are not included in Latvia’s lists 0f narcotic 
drugs, psychotropic substances and precursors and on which information 
from the European Early Warning System has been obtained or an opinion of 
a forensic authority on new psychoactive substances has been received, can be 
restricted or prohibited for 12 months (Likuma par narkotisko un psihotropo 
vielu un zāļu likumīgās aprites kārtību, 1998).
It could be considered in the framework of this article whether it would 
be feasible to formulate a proposal for a new EU regulation on the lists of new 
psychoactive active substances. For now, the lists adopted on the EU level are 
to be modified through Council Decisions. The Consolidated Version of the 
Treaty on the Functioning of the European Union, Article 288, does not estab-
lish a direct applicability of the Council decisions (Consolidated version of the 
Treaty on the Functioning of the European Union, 2008). The Court of Justice 
of the EU, however, has recognized that some decisions may have direct appli-
cability; however, in cases when they refer to an EU country as the addressee 
only (Judgement 10 November 1992, Hansa Fleisch), this is not the case with 
the Council Decisions on new psychoactive substances. Therefore, it could be 
feasible to provide for a system where the new psychoactive substances are 
acknowledged to be controlled substances through a regulation instead of a 
council decision. The Consolidated Version of the Treaty on the Functioning 
of the European Union, Article 288, establishes that every regulation shall be 
binding in its entirety and directly applicable in all Member States (Consoli-
dated version of the Treaty on the Functioning of the European Union, 2008). 
An example of a similar regulation could be drawn from the Commission 
Implementing Regulation (EU) 2015/1998 of 5 November 2015, laying down 
detailed measures for the implementation of the common basic standards on 
aviation security (Text with EEA relevance) that inter alia enlists articles that 
are prohibited to be carried into security restricted areas of airports (European 
Commission, 2015).
As mentioned above, the schedules established by the UN convention and 
EU council decisions also serve as a basis for lists of controlled narcotic and 
psychotropic substances established by national legal acts; however, the scope 
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of the national acts differ, i.e., there are certain substances that are placed un-
der measures of control in some Member States of the EU only (EMCDDA, 
2008). The differences could lead to some questions in regard of the basic 
EU principle of mutual recognition. However, norms established in the legal 
documents of the European Union preclude the application of the principle 
towards narcotic and psychoactive substances. E.g. Directive 2001/83/EC of 
the European Parliament and of the Council of 6 November 2001 on the Com-
munity code relating to medicinal products for human use, Article 83 states 
that the Directive “shall not prevent the application of more stringent require-
ments laid down by Member States in respect of the wholesale distribution of 
narcotic or psychotropic substances within their territory”. Similarly, Council 
Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-
assessment and control of new psychoactive substances, Article 9, states that 
“nothing in this Decision shall prevent a Member State from maintaining or 
introducing on its territory any national control measure it deems appropriate 
once a new psychoactive substance has been identified by a Member State”. 
Moreover, the European Commission, although acknowledging that the prin-
ciple of mutual recognition in respect of narcotic and psychotropic substances 
is to be applied on a case by case basis, still has put forward a position that 
“when competent authorities of a Member State intend to adopt a decision that 
could prohibit the marketing of those substances lawfully marketed in another 
Member State on other than safety or health grounds, the Regulation (EC) 
No 764/2008 should apply. This is the case, for example, when a psychoactive 
substance lawfully marketed in another Member State is denied for reasons 
based on the denomination, size, composition, etc.” 
The aforementioned norms shall be considered as a sufficient argument 
for a statement that opioids acknowledged to be narcotic or psychotropic sub-
stances in one Member State can still stay outside the scope of control meas-
ures directed to narcotic and psychotropic substances in other Member States. 
However, it should also be noted that the EU documents cited still use termi-
nology “narcotic or psychotropic substances” towards substances that are ac-
knowledged to be controlled substances in one of the Member States only. Tak-
ing into account that the same documents refer to narcotic and psychotropic 
substances as “classified as a narcotic or a psychotropic substance within the 
ISSN 2351-6097   eISSN 2538-8754   KRIMINOLOGIJOS STUDIJOS 2019/7
34
meaning of the international conventions in force, such as the United Nations 
Conventions of 1961 and 1971” only, some clarifications would be necessary. 
3. Legal Definitions of New Psychoactive  
Substances: List Approach and Its Alternatives
The term “new psychoactive substances” covers wider array of substances 
than uncontrolled opioids only. Council Decision 2005/387/JHA of 10 May 
2005 on the information exchange, risk-assessment and control of new psy-
choactive substances denotes that “‘new psychoactive substance’ means a new 
narcotic drug or a new psychotropic drug in pure form or in a preparation”, 
“‘new narcotic drug’ means a substance in pure form or in a preparation, that 
has not been scheduled under the 1961 United Nations Single Convention on 
Narcotic Drugs, and that may pose a threat to public health comparable to 
the substances listed in Schedule I, II or IV”, and “‘new psychotropic drug’ 
means a substance in pure form or in a preparation that has not been sched-
uled under the 1971 United Nations Convention on Psychotropic Substances, 
and that may pose a threat to public health comparable to the substances listed 
in Schedule I, II, III or IV”. The Council Decision takes out from the scope of 
these terms a) substances currently listed in any of the schedules to the 1961 
United Nations Single Convention on Narcotic Drugs, and the 1971 United 
Nations Convention on Psychotropic Substances, b) precursors in respect of 
which Council Regulation (EEC) No 3677/90 of 13 December 1990 laying 
down measures to be taken to discourage the diversion of certain substances 
to the illicit manufacture of narcotic drugs and psychotropic substances, and 
Regulation (EC) No 273/2004 of the European Parliament and of the Council 
of 11 February 2004 on drug precursors provide for a Community regime. 
The Council Decision establishes that new psychoactive substances are to be 
brought under measures of control by the Council through the initiative of the 
Commission which in its own turn should be based on Risk Assessment Re-
port of the EMCDDA. What should be noted in this respect is that the Council 
Decision adopts the same “list approach” similar to the one established by the 
1961 United Nations Single Convention on Narcotic Drugs, the 1971 United 
Nations Convention on Psychotropic Substances, and most of the national 
laws related to drug trafficking of the Member States. Thus, it could be stated 
Algimantas Čepas, Radosav Risimović. Mechanisms and Methods for Placing New ...
35
that international, EU and national legal acts follow the same approach both 
towards traditional drugs and new psychoactive substances, i.e. that measures 
of control can be applied to these substances only in cases when they are for-
mally acknowledged to be controlled before a certain person is found in pos-
session of the substances.
It has been already acknowledged at least in the practice of law enforce-
ment that the list approach is lacking, especially when applied to new psy-
choactive substances. The growth of the numbers of new psychoactive sub-
stances is accelerating. For example, there were only 85 substances listed in the 
schedules of the United Nations Single Convention on Narcotic Drugs in 1961, 
250 substances listed in the schedules of the 1961 and 1971 conventions in 
2013 (the lists have not been significantly expanded since then) (Corazza et al., 
2017). While during the first 9 months of 2016 EMCDDA and Europol have 
issued 57 formal notifications of new psychoactive substances (NPS), 1 risk 
assessment report was submitted to the Council and the EC, and 5 EU Early-
Warning Systems (EWS) Alerts and 3 EU Early-Warning Systems Advisories 
have been issued (General Secretariat of the Council. Standing Committee on 
Operational Cooperation on Internal Security (COSI), 2016).
Some Member States are searching for the ways to control new psychoac-
tive substances that are not covered by the lists-based legal norms regulating 
narcotic and psychoactive substances. Several examples are worth mentioning.
The produced by the European Monitoring Centre for Drugs and Drug 
Addiction “New psychoactive substances in Europe: Legislation and prosecu-
tion — current challenges and solutions” states that: “Governments in Europe 
have responded in different ways to the challenges posed by the market in new 
psychoactive substances (NPS). Among these measures designed to reduce the 
availability and use of NPS, three broad and sometimes overlapping groups of 
legal responses can be identified. In the first group, existing laws that focused 
on consumer or health protection or medicines have been used. In the second 
group, drug laws have been modified, most commonly by introducing group 
definitions of substances under control. In the third group, innovative new 
laws have been developed to address these substances, in a few cases even de-
fining a psychoactive substance by its effect rather than its chemical structure.” 
(EMCDDA, 2016). 
ISSN 2351-6097   eISSN 2538-8754   KRIMINOLOGIJOS STUDIJOS 2019/7
36
4. Generic Legislation on New  
Psychoactive Substances 
Most of the Member States that deal with new psychoactive substances 
retain the “list approach” (analogue scheduling) to new psychoactive sub-
stances, establishing a more rapid procedure (ministerial orders instead of 
regulations passed by governments) for their inclusion in the lists only. How-
ever, the norms establishing “group definitions” (generic scheduling/generic 
bans) could count as a more promising practice. Generic bans are based on the 
structure of molecules of questionable substances and imply the prohibition 
of a group of psychoactive substances (Chatwin et al., 2017). This practically 
means that all substances originating from the same “molecular skeleton” are 
banned in this way (Kavanagh et al., 2014). In other words, generic bans crim-
inalize those groups of substances that have the same chemical structures as 
the drugs that have already been banned (Hughes et al., 2017). The purpose 
of generic bans is to eliminate the basic weakness of the traditional approach 
of individual listing of new psychoactive substances (NPS), which can be re-
duced to the fact that the legislature, as a rule, loses a “time race” against drug 
dealers, who respond more quickly and distribute new drugs on a daily basis. 
Thus, all substances which have yet to emerge on the market of narcotic drugs 
are banned if their chemical composition is similar to that of banned drugs 
(chemical analogues) (Amsterdam et al., 2013). 
The generic approach to problem solving has had some success in sup-
pressing the drug market in Japan, particularly regarding simple chemical 
compounds whose number has been significantly reduced (e.g. naphthoylin-
doles – a class of synthetic cannabinoids and cathinones) (Kikura-Hanajiri, 
2016). Some Member States of the European Union also base their drug pol-
icies on similar models. For example, the Austrian Law on New Psychoactive 
Substances establishes that “The Federal Minister or the Minister for Health 
may also define classes of chemical substances if this measure appears to be 
more appropriate than designation of individual new psychoactive substances” 
(Neue-Psychoaktive-Substanzen-Gesetz, 2019). A similar norm is established 
in the Polish Law on Counteracting Drug Addiction: “The Minister competent 
for health shall define by an ordinance a list of new psychoactive substances 
covering both these substances or groups of them” (Ustawa z dnia 29 lipca 
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2005 r. o przeciwdziałaniu narkomanii, 2005). The Estonian Act on Narcot-
ic Drugs and Psychotropic Substances and their Precursors defines narcotic 
drugs and psychotropic substances as “substances and substances belonging to 
the groups listed in the lists established on the basis of subsection 31 (1) of this 
Act, as well as isomers, esters, ethers and salts of these substances, and medici-
nal products containing such substances”, as well as provides a legal definition 
of a group of narcotic drugs and psychotropic substances, namely “substances 
of the same general structural formula are substances of the list listed on the 
basis of subsection 31 (1) of this Act” (in this sense the Estonian Act seems kind 
of restrictive, i.e. group of narcotic substances could be understood only as a 
group of similar substances that are already included in the list individually) 
(Narkootiliste ja psühhotroopsete ainete ning nende lähteainete seadus, 1997). 
A seemingly similar approach can be found in the Danish Law on Narcot-
ics, establishing that the term “drugs” denote inter alia “products of any kind 
[…] as well as processed forms of the relevant substances, drugs, plants and 
fungi, provided that the processing does not lead to a chemical change of the 
substances” (Forskrift om narkotika, 2013). The Lithuanian Law on Control of 
Narcotic and Psychotropic Substances (Art. 3) also provides that new psycho-
active substances can be enlisted into the lists of controlled substances by their 
specific names or the group names of their derivatives (Lietuvos Respublikos 
narkotinių ir psichotropinių medžiagų kontrolės įstatymas, 2019). 
This approach is a more promising one. However, some drawbacks should 
also be noted. 
First, there is a lack of agreed criteria for the classification of narcotic and 
psychotropic substances. A set of criteria being applied covers the chemical 
structure of substances, their clinical use, their origin, sited of action of sub-
stances, action prototypes, behavioural effects of substances (Niesink, 1999). 
Many substances can be classified into more than one category under the same 
criteria applied: many drugs, while having similar chemical structures, have 
different pharmacological properties; many drugs have similar pharmacologi-
cal properties, but different behavioural effects (Niesink, 1999), etc. 
Second, chemical analogues do not always have the same effect as banned 
substances, because their effect depends not only on the chemical structure 
but also on the relationship with the receptor. For example, cocaine and atro-
pine have the same chemical structure but different pharmacological effects 
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(cocaine causes severe psychoactive effects and, as such, is on the list of banned 
substances, while atropine is a drug widely used in medicine) (Amsterdam et 
al., 2013). Also, a cannabidiol (CBD) is a phytocannabinoid which has a simi-
lar chemical structure to that of a tetrahydrocannabinol (THC); however, it 
has psychotropic effects (antipsychotic effects – it reduces anxiety in patients), 
which are opposite from those of THC (de Mello Schier et al., 2012). Accord-
ingly, generic bans may also encompass substances with no psychoactive effect. 
The consequences of the application of these regulations may be the prosecu-
tion of persons who manufacture, supply the market or use substances that are 
not drugs but rather medicines or related substances that do not have harmful 
properties of drugs. It appears that generic bans can be an obstacle to medical 
research aimed at finding new drugs for treating very serious diseases (Grob 
et al., 2011). This problem may be solved by enacting exemptions from generic 
bans on groups of compounds. However, this would require a complicated and 
expensive examination of a large number of complex chemical compounds, as 
well as time, which is a deficient resource in the fight against NPS. This would 
also mean the return to the individual consideration of each questionable sub-
stance, although the generic approach should represent a step forward in rela-
tion to the traditional NPS regulation. On the other hand, certain substances 
(synthetic cannabinoids - JWH-018, JWH-250, CP-59,540, CP-47,497) have a 
different chemical structure from the banned substances but the same psycho-
active effect (a THC-like effect). This means that these substances should be 
banned by the individual listing of prohibited substances, which again brings 
us back to the traditional model despite all its flaws (Amsterdam et al., 2013).
Third, all new psychoactive substances are being created in order to bypass 
rigid characteristics of the substances under control. Thus, establishing the cri-
teria of groups of substances instead of criteria (characteristics) of individual 
substances would only mean that persons engaged in production of new psy-
choactive substances shall seek for creation substances to avoid more general 
criteria. It is especially the case with the most complex chemical compounds 
that may have several hundred analogues; generic bans are not an instrument 
for a successful suppression of NPS (Amsterdam et a., 2013). Vice versa, it is 
difficult to assess the possible psychoactive effect of a substance which does not 
yet exist or does not exist on the market of narcotic drugs. For example, me-
phedrone (also known as miaow-miaow) was banned in the United Kingdom 
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in 2010, even though there was no evidence of its harmful effects. It was subse-
quently found that mephedrone was one of the least harmful NPS, compared 
to alternatives to drug use (Nutt, 2011). Moreover, mephedrone had a positive 
impact on public health in this country. In 2009, it was found that deaths from 
cocaine had decreased. As an alternative to cocaine, users started consuming 
mephedrone, which reduced cocaine deaths. Therefore, care should be taken 
when banning substances with a psychoactive effect, and before reaching any 
decision; both the harmful effects and risks of their use should be taken into 
account, as well as the possible benefits. Caution is needed not only because 
of the possible benefits (e.g. customs revenues) from NPS the prohibition of 
which is being considered, but primarily because of the fact that an (un)justi-
fied ban on certain substances depends on whether their users and persons 
who are supplying the drug market will be prosecuted and punished.
Thus, last but not least, from the standpoint of the law, the greatest weak-
ness of generic bans is that they raise certain question from the standpoint of 
the principle of legality, the fundamental principle on which criminal law rests. 
An average person should know what is punishable at the time of the commis-
sion of an offense, which is, with the application of generic bans, practically 
unachievable due to their complexity. Can an average citizen be expected to 
have knowledge of chemical compounds that is necessary for understanding 
generic bans? This opens up the problem of perpetrators invoking a mistake 
of law, that is, the misconception regarding the illegality of the act committed.
5. Blanket Bans of New Psychoactive Substances
Similar remarks apply to another group of solutions proposed – innovative 
new laws that have been developed to address these substances, in a few cases 
even defining a psychoactive substance by its effect rather than its chemical 
structure. Laws of some Member States (e.g. Austria) establish definitions of 
“psychoactive effects” based on the definition established in the Single Con-
vention on Narcotic Drugs of 1961: “Central nervous system stimulation or 
depression, resulting in hallucinations or disturbances in motor function 
or thinking or behaviour or perception or mood” (Neue-Psychoaktive-Sub-
stanzen-Gesetz, 2019). Others formulate their own, sometimes more restric-
tive, definitions, e.g. the Portuguese law defines a psychoactive effect as an 
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effect “on the central nervous system, which may induce significant alterations 
in motor function as well as mental functions, namely reasoning, judgment 
and behaviour, often with delusional states, hallucinations or extreme eupho-
ria, and may cause dependence” (Decreto-Lei n.º 54, 2013). However still these 
definitions usually serve as criteria to be followed for creation of lists of nar-
cotic and psychoactive substances and not as alternatives to the lists. Thus, the 
doubts provided in regard of other two groups are applicable.
However, the fourth and the most promising group of solutions proposed 
should be considered. There are several states that establish that every psychoac-
tive substance in considered under the measures of control except when a formal 
authorization from the government has be provided, so-called blanket bans. 
The approach has been entrenched in the Psychoactive Substances Act 
2016, passed by the Parliament of the United Kingdom, stating that:
“(1) A person commits an offence if—
(a) the person intentionally imports a substance,
(b)  the substance is a psychoactive substance,
(c)  the person knows or suspects, or ought to know or suspect, that the sub-
stance is a psychoactive substance, and
(d)  the person—
(i)  intends to consume the psychoactive substance for its psychoactive 
effects, or
(ii)  knows, or is reckless as to whether, the psychoactive substance is 
likely to be consumed by some other person for its psychoactive ef-
fects.” (Psychoactive Substances Act, 2016).
A similar regulation could be found in the Romanian Law on combating 
operations with products susceptible to psychoactive effects, other than those 
provided by the normative acts in force, establishes: 
“(1) Operations with products that are susceptible to psychoactive effects shall 
be subject to authorization under the conditions established by this law.
 (2) Until authorization is obtained, it is forbidden to carry out operations with 
the product subject to authorization.
 3.  A product is considered to be susceptible to psychoactive effects if it can 
reasonably be expected to cause psychoactive effects and if it is not used or 
could not be used for the purpose for which it has been produced.
 4.  Reasonableness of the matter is to be assessed on however not limited to the 
following criteria:
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 a)  absence or insufficiency of data to determine the legal status of the prod-
uct;
 b)  product characteristics, mainly composition, or lack of [medical] indica-
tion [for its use];
 c)  consumption, as a predictable purpose of the product;
 d)  the presentation of the product, its labelling, any warnings or instruc-
tions for its use, and any other indication or information relating thereto, 
or even its absence.
 (5)  Authorization is also required if product operations are carried out by 
electronic means.” (Lege nr. 194, 2011).
The blanket bans model could be foreseen to gather momentum across the 
EU in the future. It is worth noting an elaborated definition of new psychoac-
tive substances formulated by the European Commission in the Proposal for a 
regulation of the European Parliament and of the Council on new psychoactive 
substances, which reads: the European Union provide most detailed definition 
of new psychoactive substances: “new psychoactive substance means a natural 
or synthetic substance that, when consumed by a human, has the capacity to 
produce central nervous system stimulation or depression, resulting in hal-
lucinations, alterations in motor function, thinking, behaviour, perception, 
awareness or mood, which is intended for human consumption or is likely to 
be consumed by humans even if not intended for them with the purpose of 
inducing one or more of the effects mentioned above, which is neither con-
trolled under the 1961 United Nations Single Convention on Narcotic Drugs, 
as amended by the 1972 Protocol, nor the 1971 United Nations Convention 
on Psychotropic Substances; it excludes alcohol, caffeine and tobacco, as well 
as tobacco products within the meaning of Council Directive 2001/37/EC of 
5 June 2001 on the approximation of the laws, regulations and administrative 
provisions of the Member States concerning the manufacture, presentation 
and sale of tobacco products”. It should be noted that similar attitudes can be 
supported by some EU legal acts in force that could act as precedents for the 
approach being considered. For example, actually analogical regulation exists 
in regard of firearms. Directive (EU) 2017/853 of the European Parliament and 
of the Council of 17 May 2017 amending Council Directive 91/477/EEC on 
control of the acquisition and possession of weapons, Art. 1, para. 1 establishes 
that ““firearm” means any portable barrelled weapon that expels, is designed 
to expel or may be converted to expel a shot, bullet or projectile by the action 
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of a combustible propellant, unless it is excluded from that definition for one 
of the reasons listed in Part III of Annex I. Firearms are classified in Part II 
of Annex I. An object shall be considered to be capable of being converted to 
expel a shot, bullet or projectile by the action of a combustible propellant if: (a) 
it has the appearance of a firearm; and (b) as a result of its construction or the 
material from which it is made, it can be so converted”.
The main advantage of blanket bans is that they criminalize all psychoac-
tive substances without exception, both the current ones and the ones yet to 
emerge (Stevens et al., 2015). It seems that the legislature, by enacting blanket 
bans, has demonstrated its determination and managed to do what no one has 
achieved for several decades – to win the cat and mouse game with drug deal-
ers who have always had an advantage in this game.
However, numerous objections to blanket bans arising from the PSA have 
been pointed out in the literature. The main problem is that blanket bans are 
vague, thus contradicting the principle of legality as one of the fundamental 
principles of criminal law. For example, the criminal legislation of the Repub-
lic of Serbia considers narcotic drugs to be only those substances that cause 
“pathological or functional changes in the central nervous system” (Zakon o 
psihoaktivnim kontrolisanim supstancama, 2010). Similarly, the 1971 Misuse 
of Drugs Act criminalizes those substances that have the capacity to induce 
harmful effects sufficient to create a social problem (Article 1, paragraph 2). 
Under the 2016 Act, any substance capable of producing a psychoactive effect 
in a person who consumes it is deemed a psychoactive substance. A psychoac-
tive effect exists if a substance stimulates or depresses the central nervous sys-
tem, affects the mental functioning or emotional state (Article 2, paragraphs 1 
and 2 of the PSA). Therefore, it is not necessary for a substance to have nega-
tive effects on, or endanger, human health to be deemed a drug in the sense 
of this Act.
The concept of a psychoactive substance is determined using the term 
“psychoactive effect”. According to the Australian legislation, a “psychoactive 
effect” means: “a) stimulation or depression of the person’s central nervous 
system, resulting in hallucinations or in a significant disturbance in, or signifi-
cant change to, motor function, thinking, behaviour, perception, awareness or 
mood; or (b) causing a state of dependence, including physical or psychologi-
cal addiction” (Crimes Legislation Amendment (Psychoactive Substances and 
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Other Measures) Act, 2015). Accordingly, the psychoactive substance is con-
sidered to be “any substance that, when a person consumes it, has the capacity 
to induce a psychoactive effect” (Crimes Legislation Amendment (Psychoac-
tive Substances and Other Measures) Act, 2015). The Australian legislation 
provides a more precise determination of a “psychoactive effect” because it 
means, among other things, “hallucinations” or a “significant disturbance”, 
that is, it is based on the harm caused to health. Yet, it is impossible to say that 
this definition of a “psychoactive effect” solves the problem surrounding the 
vagueness of blanket bans. For example, it is unclear what is meant by a “sig-
nificant” disturbance. Interestingly, the 2016 PSA does not require any “signifi-
cant” impact on mental functioning or emotional state. It is paradoxical that 
blanket bans pertain to drugs yet to emerge on the market, for it is impossible 
to say with certainty that drugs which have not emerged yet will cause inherent 
harmful effects to health (Barratt et al., 2017).
The vague definition of a “psychoactive effect” contained in the PSA leads 
to the dangers of applying the Act to the substances that do not induce harmful 
effects as traditional drugs do, or to substances that have negligible psychoac-
tive effects. Blanket bans do not solve the problem of those NPS that are not 
sold as drugs, but rather as different products labelled “not for human con-
sumption,” which has already been discussed in this article.
The scientific literature takes the view that a very broad application of the 
PSA and the violation of the principle of legality will not be prevented by en-
acting exemptions (Reuter et al., 2017). Additionally, it has been emphasized 
that screening techniques to determine a psychoactive effect are not reliable, 
because only clinical studies can provide accurate data on the psychoactive ef-
fect of a substance (Stevens et al., 2015). In spite of this, a psychoactive effect, 
according to the PSA, is determined after quick screening checks (Wadsworth 
et al., 2017). It should be emphasized that clinical studies require time (and 
significant costs), which represents a deficient resource in the effort of sup-
pressing NPS.
Also, blanket bans may cause certain difficulties during the prosecution 
of drug-related offenders. The burden of proof is on the prosecution, which 
will face numerous difficulties in proving the subjective element of an offense, 
that is, that the perpetrator knew or suspected, or was obliged to know or to 
suspect that, in a certain case, it was a substance that produced psychoactive 
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effects (Stevens et al., 2015). Thus, the consequence of blanket bans is a crimi-
nal proceeding against drug dealers and drug users, which will last longer, 
resulting in significant additional costs.
6. Regulation of New Psychoactive Substances through 
Consumer Protection and Health Protection Laws
In some cases, it has been considered whether the issues raised by the 
principle of legality could be avoided through avoidance of criminalization 
of new psychoactive substances itself, leaning instead onto laws that deal with 
consumer protection and health protection. In this way dealing with new psy-
choactive substances would still be considered illegal however the regulation 
would be less rigid than applied towards narcotic drugs. Generally, these laws 
(health and consumer protection laws) are devoted to guarantee sufficient 
quality of services and products (including substances). Therefore, the applica-
tion of the regulation to exempt a new psychoactive substance from the market 
would mean:
a) the new psychoactive substance could be treated as a medicinal prod-
uct and could circulate in the market under certain circumstances 
(thus, such an acknowledgement would carry in itself a certain part of 
recognition given to a new psychoactive substance and would burden 
inclusion of the new psychoactive substance in the list of controlled 
drugs afterwards), and
b)  the new psychoactive substance is precluded from circulation in the 
market due to the insufficient quality of it. When taking into account 
that the new psychoactive substances are usually defined as substances 
that provide an effect similar to the substances included in the lists of 
narcotic and psychotropic substances, this line of arguments would 
lead to an illogical conclusion that a certain NPS is precluded from cir-
culation due to the fact that it produces insufficient psychoactive effect.
However, the judgment of the European Court of Justice in the Joined 
Cases C-358/13 and C 181/14 actually precludes this approach to be taken 
against new psychoactive substances. It can be stated that the judgment of 
the European Court of Justice mostly rests on definitional issues. The Court 
has stated that “the term ‘medicinal product’ […] must be interpreted as not 
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covering substances […] which are not such as to entail immediate or long-
term beneficial effects for human health.” The same line of argument seems 
to be applicable to every application of consumer law towards new psychoac-
tive substances. Several Member States (e.g. Denmark, the Czech Republic, 
Sweden) are still looking for a way to overcome effects of the ECJ judgment 
by specifically mentioning that the notions of narcotic and psychotropic sub-
stances used in their respective legal acts cover pharmaceutical products (For-
skrift om narkotika, 2013; Zákon o návykových látkách a o změně některých 
dalších zákonů, 2017; Narkotikastrafflag, 1968). The same mode of thinking 
occurs in some countries outside Europe, e.g. Japan (Preedy, 2016). Following 
the arguments listed above, an approach taken by some countries (e.g. Austria, 
Finland, Ireland) to specifically exclude medicinal and pharmacological prod-
ucts from the application of drug related legal acts seems a more substantiated 
one (Neue-Psychoaktive-Substanzen-Gesetz, 2019; Huumausainelaki, 2008; 
Criminal Justice (Psychoactive Substances) Act, 2010).
7. Establishing a Legal Market  
for New Psychoactive Substances
Finally, a new approach providing for certain legalization of new psycho-
active substances should be considered. New Zealand is the first country to 
establish a legal market for new psychoactive substances by enacting the Psy-
choactive Substances Act 2013 (PSA) (Seddon, 2014). According to this ap-
proach, approval for the manufacture of NPS may be obtained from a compe-
tent state authority if manufacturers prove that the products carry a “low risk” 
of harm. Accordingly, if clinical trials in humans demonstrate that the use of a 
certain substance does not pose a significant risk to human health, then man-
ufacturers may obtain approval for the manufacture and supply of NPS (Wil-
kins, 2014). Six criteria have been established to prove that the substance in 
question carries a “low risk” of harm: 1) toxicological effects; 2) risk to public 
health; 3) potential to cause death; 4) potential to create dependence; 5) like-
lihood of misuse; 6) appeal to vulnerable populations (Rychert et al., 2016).
In this way, New Zealand abandoned the policy based on the prohibition of 
NPS, which was followed by a number of weaknesses (a continuous emergence 
of new substances on the NPS market, a slow process of adding new substances 
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to the list of banned substances, etc.) (Meacher, 2013). One of the disadvan-
tages of the NPS ban policy concerns the high costs of determining whether a 
particular substance should be added to the list of banned substances. Under 
the PSA, these costs are borne by manufacturers, rather than by government 
institutions (Wilkins, 2014). A key feature of this NPS regulation is the duty of 
manufacturers to prove that the substance they manufacture and put into circu-
lation safe regarding the preservation of health. Additionally, according to this 
concept, manufacturers are responsible for packaging and labelling substances 
whose production and putting into circulation is approved, providing the nec-
essary information important for the safe use of these substances and paying a 
certain amount of money for each product put into circulation (Meacher, 2013). 
Thus, it aims to achieve a higher degree of the protection of users while at the 
same time limiting the number of new substances on the market. The limited 
use of substances is ensured by prescribing that the approved substances may be 
purchased solely by persons aged 18, at precisely determined retail shops, that 
is, by advertising bans; all products must have a label containing information 
on potential health risks, a list of ingredients, and contact details of the National 
Poisons Centre to obtain further information (Wilkins, 2014). It turns out that 
personal use of these substances will not constitute an offense. This solution rep-
resents a major change in drug policy because drug trafficking is a very serious 
crime in all modern legislation, while keeping drugs for personal use is also an 
offense in most countries (Akgul et al., 2017).
The legislature of New Zealand wanted to abandon the policy of banning 
NPS, which has many shortcomings. The main problem faced by law enforce-
ment agencies in an attempt to suppress NPS is a cat and mouse game with 
drug dealers (Rychert et al., 2018). It is a fact that the ban on NPS cannot 
solve this problem, because each new drug on the list of banned psychoac-
tive substances is quickly replaced with a similar substance that is not on the 
list (Winstock et al., 2010). Manufacturers of NPS slightly alter the molecular 
structure of the banned substance and thus produce a new substance similar 
in chemical structure and effects to the substance on the list of banned sub-
stances (Piggee, 2009; Stackhouse, 2013; Weingarten et al., 1988). Additionally, 
the starting point of this approach is that drug abuse will never be completely 
prevented. It follows that the “harm reduction philosophy” should be accepted 
(Wilkins et al., 2013).
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The “interim regime” has been established to protect public health, because 
detailed regulations to regulate this matter have not yet been enacted by the 
competent authorities. Within this interim regime, it was foreseen to collect 
data on the potential harmfulness of substances whose production and supply 
was approved. However, the data was collected through anonymous phone calls. 
Due to the anonymity of the call, the issue of quality was raised (data provid-
ers did not often respond to key questions about the amount of substance they 
consumed, their health status, etc.) and the reliability of the data collected; this 
way of collecting data allowed manufacturers to make malicious calls in order to 
eliminate competing products from the market (Rychert et al., 2018).
During the temporary regime, the products containing a certain com-
pound were withdrawn from the market, while the products containing the 
questionable substance were not. The explanation for this inconsistency is that 
the product quality on the market has oscillated, which had an impact on the 
harmfulness of products. In other words, one compound included in the prod-
uct by one manufacturer may be harmful, yet it is perfectly safe in the product 
produced by some other manufacturer (Rychert et al., 2018).
The system that creates a legal market for NPS is based on the “low harm” 
of psychoactive substances. This term is vague because there is no generally 
accepted definition of what is meant by “low harm” when assessing new psy-
choactive substances (Wilkins et al., 2013).
It has already been mentioned that the limited use of NPS is ensured by 
prescribing that approved substances may be purchased solely by persons aged 
18, at precisely determined retail shops. However, one of the managers in the 
industry that manufactures legal NPS interviewed within the study conducted 
on the consequence of applying the PSA reported that the consumers of 80-
90% of these products represent teenagers aged 19, despite declarative state-
ments that the marketing of the industry is not aimed at young people and 
people with low income (Rychert et al., 2016). Additionally, all industry man-
agers interviewed during the survey confirmed that the prices of NPS legally 
sold were significantly reduced over time and the consumers were constantly 
looking for substances with a more potent psychoactive effect. The reason 
should be sought in the desire of industry to be competitive on the market and 
obtain a greater profit. The availability of legal NPS is being increased in this 
way, which was not the purpose of enacting the PSA. However, in spite of fi-
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nancial losses, some retailers sold NPS at higher prices than their competitors 
to secure the status of a “responsible retailer” and a more responsible client 
base in which there would be no children or minors who would have to ask 
an adult to buy a NPS for them. Consequently, this creates another possibil-
ity of misusing the regulations pertaining to legal NPS: there is a possibility 
that children and minors will consume legal NPS despite the ban on purchase. 
Adults will continue to buy NPS in shops for them. Regarding consumers’ de-
mands for more potent substances, it presents another challenge which the 
legal NPS market in New Zealand must face. The question arises as to whether 
the NPS industry will respect the regulations governing the composition of 
substances whose sale is approved or try to ignore the rules in order to meet 
customer demands and maximize profits.
Some authors believe that the legal sale of drugs (cannabis) will cause neg-
ative effects on public health (Pacula et al., 2014). According to them, the ex-
perience of alcohol and tobacco, which are legally sold, does not support the 
legalization of NPS, because when the manufacture and sale of questionable 
products is once approved, the subsequent prohibition or restrictive regula-
tion is hardly feasible for legal, political, economic, psychological, and other 
reasons.
A fundamental problem that the 2013 PSA cannot solve is the legal sale 
of NPS despite the fact that the manufacture and sale of these products is not 
approved. In fact, various products containing psychoactive compounds will 
continue to be legally sold in specialized shops, and drug users will continue 
to buy and consume them even though they are labeled “not for human con-
sumption”. The information “not for human consumption” enables the manu-
facturer and the retailer to avoid prosecution if the consumption of products 
caused harm to users’ health (Sathappan, 2014). In case of being prosecuted, 
their defense will be based on the claim that the user consumed the prod-
uct willingly, despite the clear instruction “not for human consumption” on 
the package. Accordingly, although they are not sold or advertised as drugs, 
NPS can still be sold legally, but they will be labeled with a slang name which 
can be associated with drugs (Kavanagh et al., 2014). In this regard, it should 
be noted that unapproved NPS may be cheaper in the market, more potent 
and more appealing to customers because they have the status of a “forbidden 
fruit” (Wilkins et al., 2014).
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8. Conclusions
The overview of mechanisms and methods of criminalization of new psy-
choactive substances presented in this article allows formulating certain prop-
ositions that could be discussed more thoroughly.
First, it is the view of the authors that certain legislative changes in regard 
of the control of new psychoactive substances could be made on the EU level. 
The Council Decision 2005/387/JHA establishes the competence of the Euro-
pean Council to submit new psychoactive substance to control measures by 
the qualified majority acting on an initiative presented by the Commission. 
However, it could be feasible to provide for a system where new psychoactive 
substances are acknowledged to be controlled substances through a regula-
tion instead of a council decision. An example of a similar regulation could 
be drawn from the Commission Implementing Regulation (EU) 2015/1998 
laying down detailed measures for the implementation of the common basic 
standards on aviation security (Text with EEA relevance) that inter alia enlists 
articles that are prohibited to be carried into security restricted areas of air-
ports.
Second, the practice of many states has shown that the traditional “list ap-
proach” to criminalization of narcotic drugs is not sufficient to take action to-
wards many new psychoactive substances due to the extremely rapid changes 
in composition of the substances under consideration. The practice to estab-
lish “group definitions” (generic scheduling) or defining a psychoactive sub-
stance by its effect rather than its chemical structure (blanket bans) are more 
promising, however do also suffer from some drawbacks. Alternative forms of 
legal regulation – covering new psychoactive substances by laws on consumer 
protection and health protection, as well as instances of establishment of legal 
markets for new psychoactive substances – are lacking in justification also. 
Thus, it could be generalized that no approach present in the laws overviewed 
in the article could be sufficient to address the issue of criminalization of new 
psychoactive substances in proper manner, and studies aimed to search for 
alternative ways of criminalization are necessary.,
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